Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

21st Mar 2018 07:00

RNS Number : 3562I
Venn Life Sciences Holdings PLC
21 March 2018
 

 

 21 March 2018

Venn Life Sciences Holdings Plc

("Venn" or the "Company")

Resignation of Director

 

 

Venn Life Sciences ("Venn") an Integrated Drug Development Partner offering a combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations announces that Jonathan Hartshorn is to step down from his position as Finance Director of the Company with immediate effect.

 

Tony Richardson said "Jonathan is moving on to pursue other opportunities. I would like to thank him for his contribution and wish him well in his future endeavours". The Company will in due course announce a permanent replacement but, in the meantime, the finance function will report directly to the Chief Executive Officer.

 

 

Enquiries:

 

Venn Life Sciences Holdings Plc

Allan Wood, Non-Executive Chairman

Tony Richardson, Chief Executive Officer

Tel: +353 1 5499341

Cenkos (Nominated Advisor and Joint Broker)

Mark Connelly/Steve Cox (Corporate Finance)

Tel: +44(0)20 3764 2341

 

Davy (ESM Adviser and Joint Broker)

Fergal Meegan / Matthew de Vere White (Corporate Finance)

Tel: +353 1 679 6363

Hybridan LLP (Joint Broker)

Tel: +44 (0)20 3764 2341

Claire Louise Noyce

 

About Venn Life Sciences: Venn Life Sciences is an Integrated Drug Development Partner offering a unique combination of drug development expertise and clinical trial design and management to pharmaceutical, biotechnology and medical device organisations. Venn have dedicated operations in France, Germany, the Netherlands, the UK, Ireland with partners across Europe and the US.

 

Further information in relation to Venn Life Sciences www.vennlifesciences.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABRGDXCDDBGIG

Related Shares:

ORPH.L
FTSE 100 Latest
Value8,809.74
Change53.53